Trial Profile
A prospective, cohort trial evaluated the efficacy of dolutegravir versus direct acting antivirals in chronic hepatitis C patients with and without HIV coinfection in Germany
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Daclatasvir; Dasabuvir; Ledipasvir/sofosbuvir; Ombitasvir/paritaprevir/ritonavir; Peginterferon; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Apr 2016 New trial record